Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
出版年份 2021 全文链接
标题
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
作者
关键词
-
出版物
NATURE MEDICINE
Volume 27, Issue 2, Pages 256-263
出版商
Springer Science and Business Media LLC
发表日期
2021-02-09
DOI
10.1038/s41591-020-01211-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
- (2020) Reinhard Dummer et al. LANCET ONCOLOGY
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
- (2020) Alexander M. M. Eggermont et al. JAMA Oncology
- First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
- (2020) Christian U. Blank et al. JOURNAL OF CLINICAL ONCOLOGY
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
- (2020) Alexander M. M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- (2020) Paolo A Ascierto et al. LANCET ONCOLOGY
- Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non‐Small Cell Lung Cancer
- (2019) Young Kwang Chae et al. ONCOLOGIST
- Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy
- (2019) Martine Bloemendal et al. ANNALS OF SURGICAL ONCOLOGY
- Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
- (2019) J H Lee et al. ANNALS OF ONCOLOGY
- The promise of neoadjuvant immunotherapy and surgery for cancer treatment
- (2019) Jake S O'Donnell et al. CLINICAL CANCER RESEARCH
- An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).
- (2019) Mario Mandalà et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
- (2019) Alexander M. Menzies et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
- (2019) Steve Lu et al. JAMA Oncology
- Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
- (2019) Laura Fancello et al. Journal for ImmunoTherapy of Cancer
- Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
- (2018) M T Tetzlaff et al. ANNALS OF ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
- (2018) Marie-Claude Bourgeois-Daigneault et al. Science Translational Medicine
- From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting
- (2018) Steven P. Rowe et al. Molecular Oncology
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma
- (2018) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
- (2017) Natasha K. Brockwell et al. Cancer Immunology Research
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Molecular Signatures Database Hallmark Gene Set Collection
- (2015) Arthur Liberzon et al. Cell Systems
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- HTSeq--a Python framework to work with high-throughput sequencing data
- (2014) S. Anders et al. BIOINFORMATICS
- Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
- (2014) J. Yuan et al. Cancer Immunology Research
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- Fast and accurate short read alignment with Burrows-Wheeler transform
- (2009) H. Li et al. BIOINFORMATICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now